Circulating cytokines as potential dynamic biomarkers of PD-1 blockade response and prognosis in non-small cell lung cancer
Programmed death 1 (PD-1) inhibitors have transformed the treatment of advanced non-small cell lung cancer (NSCLC), but durable responses remain limited to a subset of patients. Conventional biomarkers, including PD-L1 expression and tumor mutational b…